Real‐world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old

Aim There is insufficient evidence regarding the safety and efficacy of molecular targeted agents (MTAs) for elderly patients with hepatocellular carcinoma (HCC), who are likely to be vulnerable to adverse events (AEs) of therapy. The aim of this study was to compare sorafenib and lenvatinib use in elderly patients with HCC from the viewpoint of overall survival (OS) and rate of AE‐induced MTA discontinuation. Methods This retrospective study included patients with HCC over 80 years old who received first‐line molecular targeted therapy (MTT) at four hospitals between June 2009 and September 2019. They were divided into three groups according to the era and type of first‐line MTA: E1‐Sora (sorafenib, between 2009 and 2016), E2‐Sora (sorafenib, between 2017 and 2019), and E2‐Len (lenvatinib, between 2017 and 2019). Results The study included 173 patients (E1‐Sora, n = 79; E2‐Sora, n = 50; E2‐Len, n = 44) with a median age of 81.9 years (range, 80–93 years). Median OS was 15.1 months in the entire cohort (E1‐Sora, 12.7 months; E2‐Sora, 20.5 months; E2‐Len, 10.3 months). The rate of treatment discontinuation due to AEs was high in the entire cohort, especially in E1‐Sora and E2‐Len (49.4% in E1‐Sora, 28.0% in E2‐Sora, and 54.6% in E2‐Len, p = 0.0753). More E2‐Sora patients received subsequent MTT than E2‐Len patients (E2‐Sora, 50%; E2‐Len, 28.6%; p = 0.0111). Conclusion Both sorafenib and lenvatinib were effective and feasible for elderly patients with HCC. In terms of discontinuation due to AEs and subsequent MTT, sorafenib might be more desirable for elderly patients with HCC over 80 years.